Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Gill

Showing results (111-120 of 143) with videos related to

Pageof 15
Sort By:
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 22, 2022
Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplantRachel V Hatch, Craig W Freyer, Alison Carulli, et al.
Leukemia & Lymphoma|June 3, 2020
Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementationCraig W Freyer, Alison Carulli, Alex Ganetsky, et al.
Leukemia & Lymphoma|March 8, 2022
Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemiaMolly E Graveno, Alison Carulli, Craig W Freyer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 27, 2018
Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant RecipientsAlex Ganetsky, Jennifer H Han, Mitchell E Hughes, et al.
The Journal of Clinical Investigation|December 18, 2019
CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integrationChristopher L Nobles, Scott Sherrill-Mix, John K Everett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2015
High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity ConditioningRan Reshef, Austin P Huffman, Amy Gao, et al.
Blood|June 22, 2018
Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphomaJakub Svoboda, Susan R Rheingold, Saar I Gill, et al.
American Journal of Hematology|April 4, 2020
Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agentsGee Youn Geeny Kim, Jonathan Burns, Craig W Freyer, et al.
Haematologica|April 18, 2024
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemiaMatthew P Connor, Neeharika Prathapa, Noelle V Frey, et al.
Transplantation and Cellular Therapy|May 9, 2021
Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of StayCraig W Freyer, Shannon Gier, Mary E Moyer, et al.
Pageof 15

Showing results (111-120 of 143) with videos related to

Sort By:
Pageof 15
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 22, 2022
Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplantRachel V Hatch, Craig W Freyer, Alison Carulli, et al.
Leukemia & Lymphoma|June 3, 2020
Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementationCraig W Freyer, Alison Carulli, Alex Ganetsky, et al.
Leukemia & Lymphoma|March 8, 2022
Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemiaMolly E Graveno, Alison Carulli, Craig W Freyer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 27, 2018
Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant RecipientsAlex Ganetsky, Jennifer H Han, Mitchell E Hughes, et al.
The Journal of Clinical Investigation|December 18, 2019
CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integrationChristopher L Nobles, Scott Sherrill-Mix, John K Everett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2015
High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity ConditioningRan Reshef, Austin P Huffman, Amy Gao, et al.
Blood|June 22, 2018
Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphomaJakub Svoboda, Susan R Rheingold, Saar I Gill, et al.
American Journal of Hematology|April 4, 2020
Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agentsGee Youn Geeny Kim, Jonathan Burns, Craig W Freyer, et al.
Haematologica|April 18, 2024
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemiaMatthew P Connor, Neeharika Prathapa, Noelle V Frey, et al.
Transplantation and Cellular Therapy|May 9, 2021
Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of StayCraig W Freyer, Shannon Gier, Mary E Moyer, et al.
Pageof 15